For 2023, Riber reports net income of 3.4 million euros, compared with 0.2 million in 2022, and a current operating margin doubling to 10%, on sales up 41% to 39.3 million, driven by dynamic systems sales (+96%).

The molecular-jet epitaxy specialist expects further growth in sales and profitability in 2024. A payout of 0.07 euros per share will be proposed for the 2023 financial year.

Riber's Management Board, in agreement with the Supervisory Board, has also decided to submit to the AGM on June 19, the change from the current dual governance structure to one with a Board of Directors.

Copyright (c) 2024 CercleFinance.com. All rights reserved.